ArticleACS omega2025
From Nanocrystals and Nanocomposites to Microcrystals: The Role of Simonkolleite/ZnO in Overcoming Bacterial Resistance and Ensuring Biocompatibility.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents the innovative application of simonkolleite (SM), its nanocomposite with ZnO nanocrystals (NCs), and ZnO nano-/microcrystals to explore their bactericidal and biocompatibility properties for potential biomedical applications. A systematic evaluation of antibacterial activity, antibiofilm efficacy, reactive oxygen species (ROS) production, and Drosophila melanogaster as an in vivo model was performed. The synthesis of SM, SM/ZnO nanocomposites (NCPs), and ZnO nano- and microcrystals was performed at different annealing temperatures: SM at 100 °C, SM/Zn NCPs (63.6% and 69.5% of ZnO NCs) at 250 and 500 °C, respectively, and ZnO NCs and microcrystals (MCs) at 500 and 1000 °C, respectively. Notably, ZnO NCs and MCs have demonstrated pronounced cytotoxicity in the D. melanogaster model, correlating with their ability to rapidly generate reactive oxygen species (ROS), contributing to oxidative stress and cellular damage. The SM/ZnO NCPs (250 °C) exhibited superior biocompatibility, suggesting that the SM partial conversion to ZnO may mitigate toxicity while retaining antimicrobial efficacy. Furthermore, subinhibitory concentrations of SM effectively inhibited biofilm formation, a critical factor in bacterial resistance, highlighting their potential applications in medical device coatings and antimicrobial therapies. Collectively, this research underscores the promising role of these materials in addressing antibiotic resistance and enhancing biocompatibility in biomedical applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.